Answer
Thrombotic microangiopathy (TMA) has been reported with FEIBA for breakthrough bleeding in an emicizumab clinical trial; safety and efficacy in this setting are not established, requiring benefit–risk evaluation and close physician monitoring.
Sources for this answer
- FEIBA 100 U/ml powder and solvent for solution for infusionTakeda UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 2Document updated
Sources checked